[
  {
    "ts": null,
    "headline": "Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns",
    "summary": "Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock a strong long-term opportunity.",
    "url": "https://finnhub.io/api/news?id=dd95196df08df83dcb835a89e877361f36e0ec6beb9048b6078e84cf1c31a0ac",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752622845,
      "headline": "Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns",
      "id": 135959071,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1401241138/image_1401241138.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock a strong long-term opportunity.",
      "url": "https://finnhub.io/api/news?id=dd95196df08df83dcb835a89e877361f36e0ec6beb9048b6078e84cf1c31a0ac"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Gilead Sciences (GILD) Fell More Than Broader Market",
    "summary": "Gilead Sciences (GILD) closed at $109.06 in the latest trading session, marking a -2.7% move from the prior day.",
    "url": "https://finnhub.io/api/news?id=f2fa0cb976cf34ce1ae12eab3780032723a2b2b30f873c5548f9ed3ec698f3cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752616803,
      "headline": "Here's Why Gilead Sciences (GILD) Fell More Than Broader Market",
      "id": 135965520,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (GILD) closed at $109.06 in the latest trading session, marking a -2.7% move from the prior day.",
      "url": "https://finnhub.io/api/news?id=f2fa0cb976cf34ce1ae12eab3780032723a2b2b30f873c5548f9ed3ec698f3cc"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Fall Late Afternoon",
    "summary": "Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index dropping 1.9% an",
    "url": "https://finnhub.io/api/news?id=771fc7b13744ff6b1e39380523c15efee9d69499acaeb9d106f80b18a17de279",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752609164,
      "headline": "Sector Update: Health Care Stocks Fall Late Afternoon",
      "id": 135957951,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index dropping 1.9% an",
      "url": "https://finnhub.io/api/news?id=771fc7b13744ff6b1e39380523c15efee9d69499acaeb9d106f80b18a17de279"
    }
  },
  {
    "ts": null,
    "headline": "Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention",
    "summary": "MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.",
    "url": "https://finnhub.io/api/news?id=234aa14e8dc531e314ee40bf009e2fc982b9a5437da075a1e80232ad4fd68830",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752598440,
      "headline": "Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention",
      "id": 135957302,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.",
      "url": "https://finnhub.io/api/news?id=234aa14e8dc531e314ee40bf009e2fc982b9a5437da075a1e80232ad4fd68830"
    }
  },
  {
    "ts": null,
    "headline": "Arcellx: Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market",
    "summary": "Arcellx, Inc. advances anito-cel CAR-T therapy for relapsed/refractory multiple myeloma. Click for ACLX pivotal trials, FDA progress, and launch potential by 2026.",
    "url": "https://finnhub.io/api/news?id=75484eea6df49ac7793b4702dfc1ff44a7e1475f5fbec1d6816cb33c9b5345a9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752598279,
      "headline": "Arcellx: Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market",
      "id": 135956517,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2207973383/image_2207973383.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Arcellx, Inc. advances anito-cel CAR-T therapy for relapsed/refractory multiple myeloma. Click for ACLX pivotal trials, FDA progress, and launch potential by 2026.",
      "url": "https://finnhub.io/api/news?id=75484eea6df49ac7793b4702dfc1ff44a7e1475f5fbec1d6816cb33c9b5345a9"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=4b6f04b8309e3adf9241ea80042d2e76a775b1a147b6bac1db5d5bc3710221f3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752597420,
      "headline": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors",
      "id": 135977328,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=4b6f04b8309e3adf9241ea80042d2e76a775b1a147b6bac1db5d5bc3710221f3"
    }
  },
  {
    "ts": null,
    "headline": "Bernstein Maintains Buy Rating on Gilead Sciences (GILD) Stock",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of Bernstein maintained a “Buy” rating on the company’s stock, retaining a price objective of $120.00. The analyst’s rating is backed by a combination of factors associated with the promising prospects of the new drug, Yeztugo. The drug, which is […]",
    "url": "https://finnhub.io/api/news?id=0d97f0cf4ae35f62881cf65a06d89150cea83df57c46594cb9cddc4c0bf8addd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752595246,
      "headline": "Bernstein Maintains Buy Rating on Gilead Sciences (GILD) Stock",
      "id": 135965523,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of Bernstein maintained a “Buy” rating on the company’s stock, retaining a price objective of $120.00. The analyst’s rating is backed by a combination of factors associated with the promising prospects of the new drug, Yeztugo. The drug, which is […]",
      "url": "https://finnhub.io/api/news?id=0d97f0cf4ae35f62881cf65a06d89150cea83df57c46594cb9cddc4c0bf8addd"
    }
  },
  {
    "ts": null,
    "headline": "Connecticut wants to make generic GLP-1s. Will RFK Jr. lend a hand?",
    "summary": "Connecticut is petitioning HHS to ignore GLP-1 patents and allow the state to manufacture generics.",
    "url": "https://finnhub.io/api/news?id=daa263f5dbe6cca0711d189d5aa8a0a3b6e64ec8d39033f008cd4d1835b4ace2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752591419,
      "headline": "Connecticut wants to make generic GLP-1s. Will RFK Jr. lend a hand?",
      "id": 135958240,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Connecticut is petitioning HHS to ignore GLP-1 patents and allow the state to manufacture generics.",
      "url": "https://finnhub.io/api/news?id=daa263f5dbe6cca0711d189d5aa8a0a3b6e64ec8d39033f008cd4d1835b4ace2"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) Reaches Deal to Offer HIV Vaccine to Low and Middle-Income Nations",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it had reached an agreement with the Global Fund to Fight Aids, Tuberculosis, and Malaria. Under the agreement, the company is to make available its twice-a-year HIV pre-exposure prophylactic Yeztugo accessible to low- and middle-income countries. […]",
    "url": "https://finnhub.io/api/news?id=13c206c956e6b783dc294135b146941334b9c8c63d43b9400890673113374df3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752585044,
      "headline": "Gilead Sciences (GILD) Reaches Deal to Offer HIV Vaccine to Low and Middle-Income Nations",
      "id": 135965525,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it had reached an agreement with the Global Fund to Fight Aids, Tuberculosis, and Malaria. Under the agreement, the company is to make available its twice-a-year HIV pre-exposure prophylactic Yeztugo accessible to low- and middle-income countries. […]",
      "url": "https://finnhub.io/api/news?id=13c206c956e6b783dc294135b146941334b9c8c63d43b9400890673113374df3"
    }
  },
  {
    "ts": null,
    "headline": "Ny ag James- my office and 48 ags secured $202 million from Gilead Sciences - X post",
    "summary": "Gilead Sciences Inc: Ny ag James- my office and 48 ags secured $202 million from Gilead Sciences - X post...",
    "url": "https://finnhub.io/api/news?id=aeea062db68ee212ef0822542a9f3f9bb805adc5ad853e69eeec57444ee929c1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752582850,
      "headline": "Ny ag James- my office and 48 ags secured $202 million from Gilead Sciences - X post",
      "id": 135948672,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Gilead Sciences Inc: Ny ag James- my office and 48 ags secured $202 million from Gilead Sciences - X post...",
      "url": "https://finnhub.io/api/news?id=aeea062db68ee212ef0822542a9f3f9bb805adc5ad853e69eeec57444ee929c1"
    }
  },
  {
    "ts": null,
    "headline": "South Africa Gets R520 Million to Buy the Twice-a-Year Anti-HIV Jab - But There's a Snag",
    "summary": "SA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year anti-HIV jab, lenacapavir. Research shows the shot could help end Aids in...",
    "url": "https://finnhub.io/api/news?id=5ce7bf165b85e4fc564b43589ba767b04fcc51a0a7d5c9f8153f053e71c933ee",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752570370,
      "headline": "South Africa Gets R520 Million to Buy the Twice-a-Year Anti-HIV Jab - But There's a Snag",
      "id": 135943959,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "SA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year anti-HIV jab, lenacapavir. Research shows the shot could help end Aids in...",
      "url": "https://finnhub.io/api/news?id=5ce7bf165b85e4fc564b43589ba767b04fcc51a0a7d5c9f8153f053e71c933ee"
    }
  },
  {
    "ts": null,
    "headline": "Parnassus Value Equity Fund Q2 2025 Commentary",
    "summary": "Parnassus Value Equity Fund Q2 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=8da32aa99f91d77430a6333e00c9076e612b9dbc7e69491bd5ddc74be3c14dc2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752569820,
      "headline": "Parnassus Value Equity Fund Q2 2025 Commentary",
      "id": 135943720,
      "image": "",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8da32aa99f91d77430a6333e00c9076e612b9dbc7e69491bd5ddc74be3c14dc2"
    }
  }
]